P458: Low adherence to Mediterranean diet is associated with increased adipose tissue in patients with ulcerative colitis (UC) after pouch surgery: a cross sectional studyECCO’23 CopenhagenYear: 2023
Authors: Pfeffer-Gik, T.(1)*;Godny, L.(1);Ollech, J.(1);Wasserberg, N.(2);White, I.(2);Cohen, S.(1);Broitman, Y.(1);Avni-Biron, I.(1);Banai, H.(1);Snir, Y.(1);Yanai, H.(1);Yackobovich Gavan, M.(3,4);Shimon, I.(5);Tsvetov, G.(5);Barkan, R.(1);Dotan, I.(1);
(1)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Division of Gastroenterology, Petah Tikva, Israel;(2)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Colorectal Unit- Division of Surgery, Petah Tikva, Israel;(3)Schneider Childrens Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes- National Center for Childhood Diabetes, Petah Tikva, Israel;(4)Tel Aviv University, Dept. of Epidemiology and Preventive Medicine- School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;(5)Rabin medical center- Beilinson campus- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Institute of endocrinology- diabetes and metabolism, Petah Tikva, Israel;
P459: Hospitalization, use of biologics and surgery rates in inflammatory bowel diseases: a single-center comparative analysis between public and private healthcare systems in a tertiary unit from Latin AmericaECCO’23 CopenhagenYear: 2023
Authors: Zacharias, P.(1);Perussolo, M.(2);Magro, D.O.(3);Barauna, F.D.S.B.(2);KotzeMD- PhD, P.G.(4)*;
(1)Pontificia Unmiversidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(2)Pontificia Universidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(3)Universidade Estadual de Campinas UNICAMP, Colorectal Surgery Unit, Campinas, Brazil;(4)Pontificia Universidade Católica do Paraná PUCPR, IBD outpatient Clinics, Curitiba, Brazil;
P460: Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
(1)University College London Hospitals NHS Foundation Trust, Gastrointestinal Services, London, United Kingdom;(2)University College London, Eastman Dental Institute, London, United Kingdom;
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);
(1)Evangelisches Krankenhaus Kalk Cologne, Surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk Cologne, Gastroenterology, Cologne, Germany;Department of Surgery
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early RespondersECCO’23 CopenhagenYear: 2023
Authors: Wong, E.(1);Dulai, P.(2);Marshall, J.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
(1)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, Hamilton, Canada;(2)Northwestern University, Division of Gastroenterology, Chicago, United States;(3)Western University, Department of Medicine Division of Gastroenterology, London, Canada;(4)Medical University of Vienna, Department of Internal Medicine III Division of Gastroenterology and Hepatology, Vienna, Austria;
P463: Crohn's disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese StudyECCO’23 CopenhagenYear: 2023
Authors: Ogino, T.(1,2)*;Mizushima, T.(2);Sekido, Y.(1);Fujii, M.(3);Eguchi, H.(1);Nezu, R.(4);Ikeuchi, H.(5);Uchino, M.(5);Futami, K.(6);Okamoto, K.(7);Ajioka, Y.(8);Sugihara, K.(9);Ishihara, S.(10);
(1)Osaka University, Department of Gastroenterological Surgery, Osaka, Japan;(2)Osaka University, Department of Therapeutics for Inflammatory Bowel Diseases, Osaka, Japan;(3)Osaka University, Division of Health Sciences, Osaka, Japan;(4)Osaka Central Hospital, Department of Surgery, Osaka, Japan;(5)Hyogo College of Medicine, Department of Inflammatory Bowel Disease Surgery, Nishinomiya, Japan;(6)Fukuoka University Chikushi Hospital, Department of Surgery, Chikushino, Japan;(7)Tokyo Yamate Medical Center, Department of Coloproctology, Tokyo, Japan;(8)Niigata University, Department of Pathology, Niigata, Japan;(9)Tokyo Medical and Dental University, Department of Gastrointestinal Surgery, Tokyo, Japan;(10)The University of Tokyo, Department of Surgical Oncology, Tokyo, Japan;The Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum
P464: Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Afzali, A.(5);Abreu, M.T.(6);
(1)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Cincinnati- Cincinnati, Division of Digestive Diseases, Cincinnati, United States;(6)The University of Miami Miller School of Medicine, Medicine, Miami, United States;
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Armuzzi, A.(1)*;Rubin, D.T.(2);Schreiber, S.(3);Panés, J.(4);Fellmann, M.(5);Bartolome, L.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Chaparro, M.(10);Dubinsky, M.C.(11);
(1)IRCCS Humanitas Research Hospital- Rozzano, IBD Center, Milan, Italy;(2)University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(3)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(4)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(5)Pfizer AG, Global Medical Affairs, Zurich, Switzerland;(6)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Healthcare India Pvt. Ltd, Biostatistics, Chennai, India;(9)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(10)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD-, Gastroenterology, Madrid, Spain;(11)Icahn School of Medicine- Mount Sinai, Feinstein IBD Center, New York- New York, United States;
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1ECCO’23 CopenhagenYear: 2023
Authors: Mukherjee , R.(1);Khan , R.M.Q.(1);Liu , J.J.(2);Ananthakrishnan , A.N.(3);Lichtenstein , G.R.(4)*;Uddin , S.(1);Young , L.(1);Boules , M.(1);Adamson , P.(2);Reeves , V.(5);
(1)Takeda Pharmaceuticals U.S.A.- Inc., Medical, Lexington, United States;(2)Morehouse School of Medicine, Division of Gastroenterology, Atlanta, United States;(3)Massachusetts General Hospital and Harvard Medical School, Division of Gastroenterology, Boston, United States;(4)University of Pennsylvania, School of Medicine, Philadelphia, United States;(5)GI Associates and Endoscopy Center, GI Alliance, Jackson, United States;
P467: 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn's disease - a nationwide cohort from the epi-IIRNECCO’23 CopenhagenYear: 2023
Authors: Atia, O.(1);Goren, I.(2)*;Sharar Fischler, T.(2);Loewenberg Weisband, Y.(3);Greenfeld, S.(4);Kariv, R.(5);Ledderman, N.(6);Matz, E.(7);Magen Rimon, R.(8);Dotan, I.(2);Turner, D.(1);Yanai, H.(2);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(4)Maccabi health services, Maccabi health services, Tel Aviv, Israel;(5)Maccabi Healthcare Services, Gastroenterology, Tel Aviv, Israel;(6)Meuhedet Health Services, Meuhedet Health Services, Tel Aviv, Israel;(7)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(8)Rambam Medical Center, Pediatric Gastroenterology & Nutrition institute, Haifa, Israel;
P468: Association of uncontrolled disease with quality of life and healthcare resource utilisation in Ulcerative Colitis patients treated with advanced therapy in the United StatesECCO’23 CopenhagenYear: 2023
Authors: Igho-Osagie, E.(1);Knight, H.(2);Barlow, S.(3);Harvey, N.(2);Khandker, R.(1)*;
(1)Merck & Co. Inc, Center for Observational and Real World Evidence, North Wales- PA, United States;(2)Adelphi Real World, Autoimmune franchise, Bollington, United Kingdom;(3)Adelphi Real World, Statistics and Data Analytics, Bollington, United Kingdom;
P469: Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Navabi, S.(1)*;D'Haens, G.(2);Samaan, K.H.(3);Li, X.(3);Arora, V.(3);Redondo, I.(3);Danese, S.(4);
(1)Rutgers New Jersey Medical School, Gastroenterology- Hepatolgy and Obesity Medicine, Newark- NJ, United States;(2)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(3)Eli Lilly and Company, Immunology, Indianapolis, United States;(4)IRCCS San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit, Milano, Italy;
P470: Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Abdalla, S.(1)*;Lelievre, O.(2);Carbonnel, F.(3);Penna, C.(4);Benoist, S.(5);Brouquet, A.(5);
(1)Le Kremlin-Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicetre, France;(2)Le Kremlin Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicetre, France;(3)Le Kremlin-Bicetre University Hospital, Department of Gastroenterology, Le Kremlin-Bicetre, France;(4)Le Kremlin-Bicêtre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicêtre, France;(5)Le Kremlin Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin Bicetre, France;
P471: A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Johnson, T.(1);Reinisch, W.(2);Steere, B.(3);Milch, C.(4);Harris, C.(3);Morris, N.(3);D'Haens, G.(5);Huang, K.(1);Krishnan, V.(3)*;
(1)Indiana University, Clinical and Translational Sciences Institute, Indianapolis, United States;(2)Medical University of Vienna, Clinical Department for Gastroenterology and Hepatology, Vienna, Austria;(3)Eli Lilly and Company, Immunology, Indianapolis, United States;(4)Eli Lilly and Company, Former affiliation, Indianapolis, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;
P472: Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Karpavičiūtė, V.(1)*;Kiudelis, G.(2);Kupčinskas, J.(2);Kupčinskas, L.(2);
(1)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology, Kaunas, Lithuania;(2)Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Gastroenterology- Medical Academy, Kaunas, Lithuania;
P473: Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 studyECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Afzali, A.(2);Filip, R.(3);Rolim, A.(4);Terry, N.A.(5);Salese, L.(5);Sahoo, A.(5);Frustaci, M.E.(6);Yang, Z.(6);Andrews, J.M.(7);Danese, S.(8);Hisamatsu, T.(9);
(1)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(2)University of Cincinnati College of Medicine and Division of Digestive Diseases, Department of Internal Medicine, Cincinnati- OH, United States;(3)University of Rzeszow, Department of Gastroenterology with IBD Unit, Rzeszow, Poland;(4)Pesquisare Saúde, Coloproctology, Santo André- São Paulo, Brazil;(5)Janssen Research and Development LLC, Immunology, Spring House- PA, United States;(6)Janssen Research and Development LLC, Statistics and Decision Sciences, Spring House- PA, United States;(7)Royal Adelaide Hospital and University of Adelaide, Department of Gastroenterology and Hepatology, Adelaide, Australia;(8)IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(9)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;on behalf of the GALAXI 1 investigators
P474: Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Reijntjes, M.(1)*;Heuthorst, L.(1);Stellingwerf, M.(1);d'Haens, G.R.(2);Bemelman, W.A.(1);Buskens, C.J.(1);
(1)Amsterdam University Medical Centers, Surgery, Amsterdam, The Netherlands;(2)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;
P475: Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Majumder, S.(1,2);Melanie , L.(2);Joanne , D.(2);Naveen, S.(2);Quraishi, M.N.(2);Cooney, R.(2);Ghosh, S.(3);Iacucci, M.(1,2,4);N Shivaji, U.(1,2,4)*;
(1)University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(3)University College Cork, College of Medicine and Health- University College Cork- APC Microbiome, Cork, United Kingdom;(4)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;
P476: Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programmeECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Yarur, A.(2);Rubin, D.T.(3);Dubinsky, M.C.(4);Regueiro, M.(5);Irving, P.(6,7);Peyrin-Biroulet, L.(8,9);Goetsch, M.(10);Gu, G.(11);Wu, J.(12);Modesto, I.(13);McDonnell, A.(14);Rabbat, C.J.(15);Green, J.(16);Anthopoulos, P.(17);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(3)University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(4)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(5)Cleveland Clinic, Department of Gastroenterology- Hepatology- and Nutrition, Cleveland- Ohio, United States;(6)Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(7)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(8)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(9)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(10)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(11)Pfizer Inc, Clinical Development & Operations- Inflammation and Immunology, New York- New York, United States;(12)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(14)Pfizer- Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(15)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(16)Pfizer Inc, Field Medical- Gastroenterology, Collegeville- Pennsylvania, United States;(17)Arena Pharmaceuticals, Cardiovascular Development, San Diego- California, United States;
P477: Patient satisfaction and cost saving analysis of telemedicine in patients with inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Bossa, F.(1)*;Carparelli, S.(1);Guerra, M.(1);Cocomazzi, F.(1);Martino, G.(1);Annese, M.(1);Nardella, M.(1);Bellucci, N.(2);Gagliardi, R.(3);Terracciano, F.(1);Pacilli, L.(4);Perri, F.(1);
(1)Fondazione Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy;(2)Fondazione Casa Sollievo della Sofferenza, Information Systems, San Giovanni Rotondo, Italy;(3)University of Foggia, Department of Economics, Foggia, Italy;(4)Fondazione Casa Sollievo della Sofferenza, Health Administration, San Giovanni Rotondo, Italy;
